Literature DB >> 31897170

Prognostic significance of the tumor suppressor protein p53 gene in childhood acute lymphoblastic leukemia.

Wenwen Weng1, Ping Zhang1, Jinfei Ruan1, Yao Zhang1, Diandian Ba1, Yongmin Tang1.   

Abstract

The tumor suppressor protein p53 (TP53) gene is associated with various types of cancer; however, little is known about TP53 expression in patients with childhood acute lymphoblastic leukemia (ALL). The aim of the present study was to investigate the prognostic value of TP53 expression in childhood ALL. To achieve this, TP53 mRNA levels of 146 children with ALL and 23 child donors with idiopathic thrombocytopenic purpura were determined by reverse transcription-quantitative PCR. Relapse-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. The results demonstrated that TP53 mRNA level in patients with ALL was higher compared with that in the ITP donors (P=0.019). Patients with highly-expressed TP53 exhibited lower percentages of peripheral blood blast, higher platelet counts and inferior complete remission rates compared with patients with low expression of TP53. Survival analyses revealed that high TP53 expression was associated with poor OS and RFS in childhood ALL (P=0.018 and P=0.028, respectively) and was an independent prognostic factor in multivariate analysis for poor RFS (P<0.001) and OS (P<0.001). In conclusion, high TP53 expression is associated with poor outcomes and may be used as a molecular prognostic marker to be incorporated into an improved risk classification system for childhood ALL.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  acute lymphoblastic leukemia; childhood; prognosis; survival; tumor suppressor protein 53

Year:  2019        PMID: 31897170      PMCID: PMC6924105          DOI: 10.3892/ol.2019.11064

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  29 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome.

Authors:  Lutz Zeidler; Martin Zimmermann; Anja Möricke; Barbara Meissner; Dorothee Bartels; Christoph Tschan; André Schrauder; Gunnar Cario; Lilia Goudeva; Sarah Jäger; Richard Ratei; Wolf-Dieter Ludwig; Andrea Teigler-Schlegel; Julia Skokowa; Rolf Koehler; Claus R Bartram; Hansjörg Riehm; Martin Schrappe; Karl Welte; Martin Stanulla
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 3.  Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.

Authors:  Miron Prokocimer; Alina Molchadsky; Varda Rotter
Journal:  Blood       Date:  2017-06-12       Impact factor: 22.113

Review 4.  Childhood acute lymphoblastic leukemia: Integrating genomics into therapy.

Authors:  Sarah K Tasian; Mignon L Loh; Stephen P Hunger
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

Review 5.  Tumor-Suppressor Functions of the TP53 Pathway.

Authors:  Brandon J Aubrey; Andreas Strasser; Gemma L Kelly
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

6.  The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.

Authors:  A Stengel; W Kern; T Haferlach; M Meggendorfer; A Fasan; C Haferlach
Journal:  Leukemia       Date:  2016-09-29       Impact factor: 11.528

Review 7.  Targeting mutant p53 for efficient cancer therapy.

Authors:  Vladimir J N Bykov; Sofi E Eriksson; Julie Bianchi; Klas G Wiman
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

Review 8.  Relapsed childhood acute lymphoblastic leukaemia.

Authors:  Deepa Bhojwani; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2013-05       Impact factor: 41.316

9.  TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis.

Authors:  Peipei Xu; Xu Liu; Jian Ouyang; Bing Chen
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

10.  Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity.

Authors:  Zdenek Andrysik; Matthew D Galbraith; Anna L Guarnieri; Sara Zaccara; Kelly D Sullivan; Ahwan Pandey; Morgan MacBeth; Alberto Inga; Joaquín M Espinosa
Journal:  Genome Res       Date:  2017-09-13       Impact factor: 9.043

View more
  1 in total

1.  Identification of a Seven-lncRNA-mRNA Signature for Recurrence and Prognostic Prediction in Relapsed Acute Lymphoblastic Leukemia Based on WGCNA and LASSO Analyses.

Authors:  Haiyan Qi; Long Chi; Xiaogang Wang; Xing Jin; Wensong Wang; Jianping Lan
Journal:  Anal Cell Pathol (Amst)       Date:  2021-06-09       Impact factor: 2.916

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.